- Home
- ATNM vs PED Comparison
ATNM vs PED Comparison
Compare ATNM & PED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATNM | PED |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 49.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATNM | PED |
|---|---|---|
| Price | $1.40 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.00 | $1.50 |
| AVG Volume (30 Days) | ★ 194.8K | 148.3K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.43 |
| EPS | N/A | ★ 0.11 |
| Revenue | $90,000.00 | ★ $33,244,999.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42,943.57 | $305.89 |
| P/E Ratio | ★ N/A | $5.34 |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | $0.43 |
| 52 Week High | $2.41 | $1.00 |
Technical Indicators
Market Signals| Indicator | ATNM | PED |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 53.37 |
| Support Level | $1.33 | $0.43 |
| Resistance Level | $1.54 | $0.55 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.90 | 86.50 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.